Spots Global Cancer Trial Database for Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Official Title: A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Study ID: NCT05116800
Study Description
Brief Summary: This is an open label, two-stratum, phase 2 clinical trial evaluating the efficacy of 9-ING-41 in combination with gemcitabine/docetaxel in patients ≥10 years of age with advanced sarcoma. 9-ING-41 in combination with gemcitabine and docetaxel will lead to sustained disease control and/or increase the rates of objective response in patients with unresectable or metastatic soft tissue and bone sarcomas.
Detailed Description:
Keywords
Eligibility
Minimum Age: 10 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hasbro Children's Hospital, Providence, Rhode Island, United States
Lifespan Cancer Insitute, Providence, Rhode Island, United States
Contact Details
Name: Bradley D DeNardo, MD
Affiliation: Brown University
Role: PRINCIPAL_INVESTIGATOR
Name: Galina G Lagos, MD
Affiliation: Lifespan Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
